Results 11 to 20 of about 64,955 (112)

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

New England Journal of Medicine, 2007
Janice P Dutcher, Anil Kapoor, David F Mcdermott   +2 more
exaly   +2 more sources

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

Journal of Medical Genetics, 2023
Background Pegunigalsidase alfa is a PEGylated α-galactosidase A enzyme replacement therapy. BALANCE (NCT02795676) assessed non-inferiority of pegunigalsidase alfa versus agalsidase beta in adults with Fabry disease with an annualised estimated ...
Eric L. Wallace, O. Goker-Alpan, William R. Wilcox, M. Holida, John A Bernat, Nicola Longo, A. Linhart, Derralynn A Hughes, R. J. Hopkin, C. Tøndel, M. Langeveld, Pilar Giraldo, Antonio Pisani, Dominique P. Germain, Ankit Mehta, P. Deegan, Mária Judit Molnár, Damara Ortiz, Ana Jovanovic, M. Muriello, B. Barshop, Virginia Kimonis, B. Vujkovac, A. Nowak, Tarekegn Geberhiwot, I. Kantola, Jasmine Knoll, S. Waldek, K. Nedd, A. Karaa, Einat Brill‐Almon, Sari Alon, R. Chertkoff, Rossana Rocco, A. Sakov, David G. Warnock   +35 more
semanticscholar   +1 more source

Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use

CNS Drugs, 2023
Generalised myasthenia gravis (gMG) is a chronic, autoimmune neuromuscular disorder that can significantly impair quality of life. Several novel targeted therapeutic approaches have emerged to provide faster onset of action compared with conventional ...
Young-A. Heo
semanticscholar   +1 more source

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers

Hepatology, 2023
Background and Aims: Biliary tract cancers are rare, heterogeneous cancers with poor prognoses. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGF-βRII (a TGF-β “trap”) fused to a human IgG1 ...
C. Yoo, M. Javle, Helena Verdaguer Mata, F. de Braud, J. Trojan, J. Raoul, J. W. Kim, M. Ueno, Choong-kun Lee, S. Hijioka, A. Cubillo, J. Furuse, N. Azad, Masashi Sato, Y. Vugmeyster, A. Machl, M. Bajars, J. Bridgewater, D. Oh, M. Borad   +19 more
semanticscholar   +1 more source

Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors

Journal for ImmunoTherapy of Cancer, 2023
Background Cluster of differentiation (CD)73-adenosine and transforming growth factor (TGF)-β pathways are involved in abrogated antitumor immune responses and can lead to protumor conditions.
A. Tolcher, M. Gordon, K. Mahoney, A. Seto, Marianna Zavodovskaya, C. Hsueh, Shuyan Zhai, T. Tarnowski, J. Jürgensmeier, Susanna Stinson, A. Othman, Tianling Chen, J. Strauss   +12 more
semanticscholar   +1 more source

Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas

JAMA Network Open, 2023
Key Points Question Does interferon alfa enhance the clinical benefits of temozolomide as the first-line treatment in patients with newly diagnosed high-grade glioma (HGG)? Findings In this phase 3 randomized clinical trial study of 199 patients with HGG,
Chengcheng Guo, Qunying Yang, Pengfei Xu, M. Deng, Taipeng Jiang, L. Cai, Jibin Li, K. Sai, S. Xi, Ouyang Hui, Ming-fa Liu, Xianming Li, Zihuang Li, X. Ni, Xi Cao, Cong Li, Shao‐xiong Wu, Xiao-Jing Du, Jun Su, X. Xue, Yiming Wang, Gang Li, Zhiyong Qin, Hui Yang, Tao Zhou, Jinquan Liu, Xue-feng Hu, Jian Wang, Xiaobing Jiang, Fu-Hua Lin, Xiangheng Zhang, Chao Ke, Xiaofei Lv, Y. Lv, Wanming Hu, J. Zeng, Zheng-he Chen, S. Zhong, Hairong Wang, Yinsheng Chen, Ji Zhang, Depei Li, Y. Mou, Zhongping Chen   +43 more
semanticscholar   +1 more source

Análisis de minimización de costes de darbepoetina alfa frente a epoetina alfa en pacientes con insuficiencia renal crónica sometidos a hemodiálisis

Farmacia Hospitalaria, 2010
Introduction: Multiple studies have shown that epoetin alpha (r-HuEpo) and darbepoetin alpha (NESP) are similarly effective and safe for maintaining haemoglobin levels in patients with chronic kidney disease (CKD). Nevertheless, there is some debate over their cost-effectiveness.
C. Cuesta Grueso, J.L. Poveda Andrés, J. Garcia Pellicer, E. Romá Sánchez   +3 more
openaire   +1 more source

Cipaglucosidase Alfa: First Approval

Drugs, 2023
Cipaglucosidase alfa (Pombiliti^™) is a recombinant human acid α-glucosidase (GAA) product being developed by Amicus Therapeutics along with the enzyme stabilizer miglustat as a two-component therapy for Pompe disease.
Hannah A. Blair
semanticscholar   +1 more source

Use of erythropoiesis stimulating agents [PDF]

, 2014
UNIFESP Hospital São Paulo Setor de HemodiáliseHospital Beneficência PortuguesaUFJF Serviço de Nefrologiacentro de pesquisa IMEPENUNIFESP, Hospital São Paulo Setor de ...
Abreu, Patricia Ferreira, Bastos, Marcus Gomes, Romão Junior, João Egídio   +2 more
core   +3 more sources

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

Orphanet Journal of Rare Diseases, 2023
Background Pegunigalsidase alfa is a novel, PEGylated α-galactosidase-A enzyme-replacement therapy approved in the EU and US to treat patients with Fabry disease (FD). Objective/methods BRIDGE is a phase 3 open-label, switch-over study designed to assess
A. Linhart, G. Dostálová, Kathy Nicholls, M. West, C. Tøndel, Ana Jovanovic, Pilar Giraldo, B. Vujkovac, Tarekegn Geberhiwot, Einat Brill‐Almon, Sari Alon, R. Chertkoff, Rossana Rocco, Derralynn A Hughes   +13 more
semanticscholar   +1 more source